Grand Cayman — September 2, 2025 — Leads & Copy — Silexion Therapeutics Corp. (NASDAQ: SLXN) announced that senior management will present at the 27th Annual H.C. Wainwright Global Investment Conference, September 8-10, 2025, at the Lotte New York Palace Hotel, New York City.
The company presentation is scheduled for Tuesday, September 10, 2025, at 2:00 PM ET. An updated presentation is available on Silexion’s website in the investor section. The management team will be available for in-person one-on-one investor meetings. Investors can request a meeting through their H.C. Wainwright representative or via email at meetings@hcwco.com.
Silexion Therapeutics is focused on developing treatments for solid tumor cancers with the mutated KRAS oncogene. The company’s Phase 2a clinical trial showed a positive trend compared to chemotherapy alone. Silexion is further developing its lead product candidate for locally advanced pancreatic cancer.
Contact:
Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact:
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com
Source: Silexion Therapeutics Corp.
